March 13, 2018
The Nuclear Regulatory Commission (NRC) held the spring meeting of its Advisory Committee on Medical Uses of Isotopes (ACMUI) on March 7 and 8, 2018. The ACMUI typically has public meetings during the spring and fall of each year and holds public teleconferences as needed. The ACMUI discussed several topics of importance to SNMMI, including worldwide supply and domestic production of molybdenum-99 (Mo-99) and training and experience requirements.
|Pictured above (from left to right) at table (viewed from back): Laura Weil, patients’ rights advocate; SNMMI Vice President-Elect Vasken Dilsizian, MD; and ACMUI Chair Philip Alderson, MD, healthcare administrator representative; (viewed from front) NRC Commissioner Jeff Baran, and NRC Chairman Kristine Svinicki. On screen: Philip Alderson, MD|
Worldwide Supply and Domestic Production of Mo-99
Richard Green provided an update on the worldwide supply and domestic production including an update on the current reactors producing Mo-99. There are currently six reactors producing Mo-99 globally:
Challenges remain with irradiator disruptions (such as extended unplanned shutdowns) and rising prices from the switch to LEU. Through the American Medical Isotope Production Act (AMIPA) of 2009, the Department of Energy is helping support domestic production of Mo-99. Recently the FDA approved the first domestically-produced non-uranium based Mo-99, RadioGenix from NorthStar Medical Radioisotopes in Beloit, Wisconsin.
Training and Experience Requirements
During the NRC Commission meeting with ACMUI, Christopher Palestro, MD, presented ACMUI's comments on the training and experience requirements for all modalities (35.300 uses). He provided a brief background on the subcommittee charge for reference. SNMMI previously reported this information to members. The subcommittee recently noted two significant developments worth considering. The first is the recent approval of Lu-177 DOTATATE for treatment of somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut. The ACMUI believes these broad indications to treat the second most common gastrointestinal tumor could result in potentially high demand for Lu-177 DOTATATE. The second concern noted was the waning number of nuclear medicine physicians in the U.S. As a result, the subcommittee is considering developing an alternate pathway for 10 CFR 35.390 and will provide another update in fall 2018.